From Wall Street Journal:

Nonprofit MAPS raises over $100 million in private stock sale to fund final stages of FDA approval for MDMA to treat PTSD. The Multidisciplinary Association for Psychedelic Studies has secured significant funding to support its efforts in obtaining regulatory approval for the therapeutic use of MDMA, commonly known as Ecstasy, in treating post-traumatic stress disorder. The organization announced the successful completion of a Series A private stock sale, raising more than $100 million to advance its groundbreaking research in the pharmaceutical psychedelics industry. This funding is crucial for MAPS as they move forward in the final stages of their application for FDA approval.



Read more: Legalization Advocate MAPS Raises Money for Pharmaceutical Psychedelics